Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in bharat biotech

Bharat Biotech Scraps Mou With Brazilian Partners After Graft Allegations

Bharat Biotech signed a MoU with Precisa Medicamentos and Envixia Pharmaceuticals LL.C on November 20 for the purpose of introducing Covaxin in the territory of Brazil.

Read More

11% Of India's Covid-19 Cases Reported In Persons Aged Below 20: Govt

The outcome of these trials will depend on data emerging from the trial for the purpose of its approval and availability in the country

Read More

Bharat Biotech's Partner Ocugen Seeks Approval For Covaxin In Canada

Health Canada will make a decision upon review of the evidence submitted that supports its safety, efficacy and quality.

Read More

Documents For Covaxin Emergency Use Listing Submitted To WHO; Expect Approval At Earliest: Bharat Biotech

EUL is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies.

Read More

Ocugen Pays USD 15 Mn Upfront To Bharat Biotech For Covaxin Rights In Canada

Ocugen in a regulatory filing said it has agreed to pay another USD 10 million to Bharat Biotech within a month from the commercial launch of Covaxin in the North American country.

Read More

Bharat Biotech S Pact With Ocugen For Covaxin Expanded To Canada

Bharat Biotech on February 2 said it andOcugenInc a US-based biopharmaceutical companyhave entered into a definitive agreement to co-develop, supply, and commercialise

Read More

Indian Immunologiclas To Start Drug Substance Production For Covaxin From June

The technology transfer process was well underway and IILhas the capabilities and expertise to manufacture inactivated viral vaccines at commercial scale and under biosafety containment

Read More

Bharat Biotech's US Partner Ocugen Submits 'Master File' To FDA On Covaxin

Ocugen has submitted key information and data to date including preclinical studies, chemistry, manufacturing, and controls (CMC), and clinical studies as a Master File for FDA review and input prior to a planned EUA submission.

Read More

Bharat Biotech Submitted 90% Of Documents To WHO For Emergency Use Listing For Covaxin: Sources

The company is in the final stages of negotiations with the Food and Drug Administration of the US for conducting small-scale phase-III clinical trials of Covaxin in the United States

Read More

COVAXIN Production Volumes Ramped Up To 200 Million By Bharat Biotech

The company plans to produce 200 million doses of COVAXIN per annum in the good manufacturing practice (GMP) facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology,

Read More

Bharat Biotech To Ramp Up Covaxin Production By Additional 200 Million Doses

Chiron Behring Vaccines, a 100 per cent subsidiary of Bharat Biotech, is one of the largest manufacturers of rabies vaccines in the world.

Read More

Bharat Biotech's Covaxin Gets Approval For Phase 2/3 Trials On Children Aged 2 To 18

The trial will be conducted in 525 subjects at different locations, including AIIMS Patna, AIIMS Delhi and Meditrina Institute of Medical Sciences in Nagpur.

Read More

Budget Heading For Vaccination Expenditure Does Not Inhibit Centre From Using Funds: FinMin

India is facing the world's worst outbreak of COVID-19 cases with more than 3 lakh new daily cases being reported for two weeks now and the new cases reached more than 4 lakh daily over the weekend.

Read More

Bharat Biotech Commences Direct Supply Of 'Covaxin' To 14 States

The Hyderabad-based firm has started supplying its COVID-19 treatment vaccine to the states based on the allocations received by the central government.

Read More

Bharat Biotech To Produce 30 Mln Doses Of COVID Vax Next Month: CMD

The government has also approved a payment of about Rs 4,500 crore as advance to vaccine makers like Serum Institute of India (SII) and Bharat Biotech against future supplies.

Read More